Salix Pharmaceuticals, Ltd. Agrees To Pay $37 Million For Product Rights

RALEIGH, N.C.--(BUSINESS WIRE)--Dec. 7, 2005--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Norgine B.V. has granted Salix the exclusive rights to sell a patent-protected, liquid PEG bowel cleansing product, NRL944, in the United States. The product is currently under review at the U.S. Food and Drug Administration (FDA) to obtain marketing approval for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations. The product has patent protection until 2013, and additional patent protection pending that, if issued, will provide patent protection until 2023. Salix is required to make an up-front payment and regulatory and sales performance milestone payments to Norgine. Over the life of the agreement, these payments by Salix could total as much as $37 million, with the majority contingent upon achievement of regulatory and sales performance milestones. In addition, the agreement calls for Norgine to supply Salix with the product and Salix to pay Norgine royalties on net sales.

Back to news